-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardio Diagnostics To Present Data Supporting Its Technology’s Ability To Detect Non-Obstructive Coronary Artery Disease On A December 10 Investor Call

Benzinga·11/17/2026 14:22:59
Listen to the news

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, December 10, 2026, at 11 a.m. Central Time.

The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests (Epi+Gen CHD™ and PrecisionCHD™), ongoing and planned studies, reimbursement progress, and strategic growth initiatives.

A key focus of the call will be non-obstructive coronary artery disease (NOCAD), a form of disease that conventional tests, such as an invasive angiogram, can miss due to the lack of severe blockages in major arteries. Patients with NOCAD, a disproportionate share of whom are women, are frequently told their arteries are "clear," yet they remain at elevated risk of a heart attack and other major adverse cardiovascular events. Without an accessible test designed to identify non-obstructive disease, many patients may go undiagnosed and untreated. Management will present data supporting the ability of the Company’s technology to detect non-obstructive disease from a simple blood sample. Because it requires only a standard blood draw, the Company’s approach is designed to be highly scalable and accessible, without the procedural risks, radiation, or contrast dye associated with invasive coronary angiography.

Building on these data, the Company plans to pursue FDA Breakthrough Device designation for the detection of non-obstructive coronary artery disease. The FDA’s Breakthrough Devices Program is intended for technologies that may provide more effective diagnosis of life-threatening or irreversibly debilitating diseases, and designation, if granted, offers prioritized review and more interactive engagement with the FDA during development. Management will discuss why it believes its technology addresses a significant unmet need in this population, as well as the anticipated timing of its request.

Management will also discuss the commencement of testing in India, the Company’s first international market, in partnership with Dr. Lal PathLabs and Aimil, along with progress on other key growth priorities.

Webcast and Conference Call Details

Date: Thursday, December 10, 2026

Time: 11 a.m. Central Time

Webcast: https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026/dec

To access the conference call by telephone (listen-only), U.S.- and Canada-based callers should dial +1 800-450-7155 (toll-free), and callers from outside the U.S. and Canada should dial +1 857-999-9155 (standard rates apply). Participants should use the Conference ID provided below to join.

Conference ID: 6865370#

A replay of the webcast will be available via the webcast link above following the conclusion of the call.